Release:2018, Vol. 4. №1
About the authors:Pavel A. Nalimov, Postgraduate Student, Doctoral School of Social Sciences, University of Trento (Italy); firstname.lastname@example.org
This article aims to formulate the concepts of the roadmap for EEU’s pharmaceutical market development in the context of national medicines coverage. The relevance of the study lies in high import dependence of national markets, despite of a number of previously undertaken and currently implemented state programs, dedicated to pharmaceutical industries formation. In the conditions, when national pharmaceutical manufacturers cannot compete with the largest foreign producers, the obvious need is not to unite the markets themselves, but to cooperate in the fields of vital drugs production and research in order to develop innovative activity. To illustrate these aspects, the authors have studied the current difficulties with EEU’s market formation, as well as the markets’ state within medicines production and consumption, in three largest EEU’s economies: Russia, Kazakhstan, and Belarus.
In conclusion, the authors suggest a roadmap proposing the gradual formation of EEU’s pharmaceutical market and deepening of its integration into the world pharmaceutical market over the next 15 years.